Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chan SL, Wong VW, Qin S, Chan HL. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90. doi:10.1200/JCO.2015.61.5724
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Cucarull B, Tutusaus A, Rider P, et al. Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances. Cancers. 2022;14(3):621. doi:10.3390/cancers14030621
   PubMed Web of Science ®Google Scholar
• Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663–675. doi:10.1007/s12072-021-10184-9
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2023;41(1):117–127. doi:10.1200/JCO.22.00392
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/jco.20.02672
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999–1007. doi:10.1016/j.jhep.2019.01.027
   PubMed Web of Science ®Google Scholar
• Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev. 2013;39(2):199–206. doi:10.1016/j.ctrv.2012.09.004
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320–341. doi:10.1016/j.jhep.2019.10.021
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.28453
   PubMed Web of Science ®Google Scholar
• Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Network Open. 2022;5(7):e2222721. doi:10.1001/jamanetworkopen.2022.22721
   PubMed Web of Science ®Google Scholar
• Dai L, Cai X, Mugaanyi J, et al. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci Rep. 2021;11(1):19711. doi:10.1038/s41598-021-98937-2
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for Adverse Events (CTCAE) Version 5.0. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed November 27, 2017.
   Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391. doi:10.1093/annonc/mdv383
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255–289. doi:10.6004/jnccn.2019.0013
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307–319. doi:10.1016/j.jhep.2019.09.025
   PubMed Web of Science ®Google Scholar
• Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20(24):7675–7685. doi:10.3748/wjg.v20.i24.7675
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol. 2014;77(6):929–938. doi:10.1111/bcp.12231
   PubMed Web of Science ®Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309. doi:10.1053/j.gastro.2017.02.009
   PubMed Web of Science ®Google Scholar
• Shen J, Wang X, Wang N, et al. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. Front Cell Infect Microbiol. 2023;13:1179689. doi:10.3389/fcimb.2023.1179689
   PubMed Web of Science ®Google Scholar
• Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol. 2016;22(4):458–465. doi:10.3350/cmh.2016.0054
   PubMedGoogle Scholar
• Lin Z, Zhang X, Zhou Y, et al. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer Immunol Immunother. 2022;71(5):1247–1255. doi:10.1007/s00262-021-03082-4
   PubMed Web of Science ®Google Scholar
• Chan SL, Yip TC, Wong VW, et al. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med. 2020;9(19):7052–7061. doi:10.1002/cam4.3378
   PubMed Web of Science ®Google Scholar
• Wu CJ, Lee PC, Hung YW, et al. Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(11):2631–2643. doi:10.1007/s00262-022-03185-6
   PubMed Web of Science ®Google Scholar
• Yang X, Chen B, Wang Y, et al. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol Int. 2023;17(1):1–11. doi:10.1007/s12072-022-10480-y
   PubMedGoogle Scholar
• Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. 2015;62(3):784–791. doi:10.1002/hep.27729
   PubMed Web of Science ®Google Scholar
• Lui TKL, Cheung KS, Leung WK. Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study. Hepatol Int. 2022;16(4):879–891. doi:10.1007/s12072-022-10370-3
   PubMed Web of Science ®Google Scholar
• Gao B, Yang F, Zheng D, et al. Transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors for advanced hepatocellular carcinoma: a propensity score matching analysis. J Hepatocell Carcinoma. 2023;10:2265–2276. doi:10.2147/jhc.S443041
   PubMed Web of Science ®Google Scholar
• Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. doi:10.3389/fimmu.2022.848387
   PubMed Web of Science ®Google Scholar
• Han Z, Yang F, Zhang Y, et al. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: a retrospective study. Front Oncol. 2022;12:1029951. doi:10.3389/fonc.2022.1029951
   PubMed Web of Science ®Google Scholar
• Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol. 2014;20(34):12039–12044. doi:10.3748/wjg.v20.i34.12039
   PubMed Web of Science ®Google Scholar
• Sun X, Hu D, Yang Z, et al. Baseline HBV loads do not affect the prognosis of patients with hepatocellular carcinoma receiving anti-programmed cell death-1 Immunotherapy. J Hepatocell Carcinoma. 2020;7:337–345. doi:10.2147/JHC.S278527
   PubMed Web of Science ®Google Scholar